中金：内地商业健康险发展有望开启新时代 关注四大领域

Core Viewpoint - The report from CICC highlights that recent policy initiatives from four Chinese regulatory bodies aim to address the challenges faced by the commercial health insurance sector, potentially leading to a new era of development in the industry [1][2]. Group 1: Policy Initiatives - The China Insurance Industry Association is promoting the establishment of model clauses for commercial health insurance and a drug payment list to standardize product design and enhance coverage [2]. - The China Actuarial Society is advancing the creation of net cost tables for commercial health insurance and innovative drug cost assessments to fill data gaps in pricing and improve risk quantification [2]. - The China Banking and Insurance Regulatory Commission is working on optimizing health insurance product checks, integrating medical insurance and commercial insurance data, and upgrading data infrastructure to resolve issues related to data silos [2]. - The China Banking and Insurance Asset Management Association is guiding insurance funds to support the development of the medical, health, and elderly care industries, injecting more patient capital into the sector [2]. Group 2: Investment Opportunities - The report suggests focusing on leading internet platforms and large insurance groups that are committed to building systematic payment solutions for commercial insurance [2]. - It also recommends investing in leading brokerage channels and related entities that excel in corporate group insurance with higher fundraising efficiency [2]. - Companies that continuously enhance their health insurance operational capabilities or benefit from the health insurance market's growth, including reinsurers and insurers, are highlighted as potential investment targets [2]. - Additionally, pharmaceutical and medical service companies that stand to gain from the incremental growth of commercial insurance payments are identified as investment opportunities [2].